Navigation Links
ResMed Announces Deferred Conversions in Connection With Stock Split
Date:8/13/2010

SYDNEY, Aug. 12 /PRNewswire-FirstCall/ -- ResMed, Inc. (NYSE: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)

As advised in the Company's 6 August announcement:

  • Stockholders of record on the New York Stock Exchange at the close of trading on August 17, 2010 will receive one additional share of common stock for each share held on that date.  The common stock will be distributed to shareholders on or about August 30, 2010, by ResMed's NYSE transfer agent, American Stock Transfer and Trust Company, LLC.  The common stock is expected to begin trading on a post-split basis on the NYSE beginning on August 31, 2010, or one day following the distribution date.
  • Holders of CHESS Depositary Interests (CDIs) on the Australian Stock Exchange will also receive a bonus issue of one additional CDI for every CDI held on the ASX record date of August 18, 2010. Unlike the shares on the NYSE, the existing CDIs will be quoted on an "ex-bonus" basis on August 12, 2010 on the ASX (ASX: RMD), and bonus CDI's will be quoted on a deferred settlement basis (ASX: RMDBN).  The bonus CDIs will be distributed by ResMed's ASX share registry, Computershare Limited, on or about August 31, 2010, and normal trading will begin on the following day.

Due to the difference in market practice between the NYSE and ASX, ResMed applied for and has been granted a waiver of rules 13.9.4  and 13.9.9 of the ASX Settlement Operating Rules, allowing it to defer the processing of conversions (transmutations) between its Common Stock and CDI registers that are lodged in the period from and including 12 August 2010 up to and including 31 August 2010.  Therefore, no conversions (transmutations) will be processed during this time. Processing of conversions will re-commence on 1 September 2010.

About ResMed

ResMed is a leading developer, manufacturer and distributor of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders.  The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed, Inc., San Diego, on (+ 1 858-836-5971), or Brett Sandercock at ResMed Limited, Sydney, on (+61 2) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.


'/>"/>
SOURCE ResMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Inc. to Present at Upcoming Conferences
2. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
3. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
4. ResMed Acquires Laboratoires Narval
5. Trubion Announces Dates for Second-Quarter and First-Half 2010 Earnings Conference Call
6. Mylan Announces Completion of Add-On Offering of Senior Notes
7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2010 Results
8. ProUroCare Medical Inc. Announces Completion of Warrant Replacement Offering
9. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
10. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
11. Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... VILLAGE, Calif. , Dec. 6, 2016 ... privately held, clinical-stage medical dermatology and aesthetics ... plc, a privately held specialty pharmaceutical company ... common inflammatory skin conditions, including psoriasis, atopic ... of the agreement, Sienna will make an ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... , Dec. 6, 2016  Regulus Therapeutics Inc. ... leading the discovery and development of innovative medicines ... candidates at its R&D day, held in ... RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for ... RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for ...
Breaking Medicine Technology:
(Date:12/7/2016)... Hamden, CT (PRWEB) , ... December 07, 2016 , ... ... has prompted an outpouring of comments on social media that offer a rare glimpse ... adult psychiatrist, leading ADHD authority and New York Times bestselling author, has described people ...
(Date:12/7/2016)... ... 2016 , ... They are musicians and librarians, fashion designers and fitness instructors, ... New England and around the nation. What do they have in common? All have ... beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is now promoting to the US market its advanced highly customizable contact technology ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
Breaking Medicine News(10 mins):